The toxicity of rifampicin polylactic acid nanoparticles againstMycobacterium bovis BCGand human macrophage THP-1 cell line
Authors:
Open Access
- 6 November 2015
- conference paper
- Published by IOP Publishing in IOP Conference Series: Materials Science and Engineering
- Vol. 98 (1) , 012017
Abstract
Tuberculosis is rapidly becoming a major health problem. The rise in tuberculosis incidence stimulates efforts to develop more effective delivery systems for the existing antituberculous drugs while decreasing the side effects. The nanotechnology may provide novel drug delivery tools allowing controlled drug release. Rifampicin is one of the main antituberculous drugs, characterized by high toxicity, and Poly (L-lactic acid) (PLLA) is a biodegradable polymer used for the preparation of encapsulated drugs. The aim of our work was to evaluate the toxicity of rifampicin-PLLA nanoparticles against Mycobacterium bovis BCG using human macrophage THP-1 cell line. Our data demonstrate that rifampicin-PLLA is effective against M. bovis BCG in the infected macrophages. The drug is inducing the dysfunction of mitochondria and apoptosis in the macrophages and is acting as a potential substrate of Pgp thereby modulating cell chemosensitivity. The severity of the toxic effects of the rifampicin-PLLA nanoparticles is increasing in a dose-dependent manner. We suggest that free rifampicin induces death of M. bovis BCG after PLLA degradation and diffusion from phago-lysosomes to cytoplasm causing mitochondria dysfunction and affecting the Pgp activity.Keywords
This publication has 18 references indexed in Scilit:
- Preparation and Drug-Release Kinetics of Porous Poly(L-lactic acid)/Rifampicin Blend ParticlesISRN Polymer Science, 2014
- Recent advances in polymeric microspheres for parenteral drug delivery—part 2Expert Opinion on Drug Delivery, 2012
- Recent advances in polymeric microspheres for parenteral drug delivery – part 1Expert Opinion on Drug Delivery, 2012
- Rifampicin and Parkinson’s diseaseNeurological Sciences, 2012
- Tuberculosis: from molecular pathogenesis to effective drug carrier designDrug Discovery Today, 2012
- Present status of nanoparticle research for treatment of TuberculosisJournal of Pharmacy & Pharmaceutical Sciences, 2011
- New old challenges in tuberculosis: Potentially effective nanotechnologies in drug deliveryAdvanced Drug Delivery Reviews, 2010
- Confronting the scientific obstacles to global control of tuberculosisJournal of Clinical Investigation, 2008
- Structural Mechanism for Rifampicin Inhibition of Bacterial RNA PolymeraseCell, 2001
- Rifampin Reduces Production of Reactive Oxygen Species of Cerebrospinal Fluid Phagocytes and Hippocampal Neuronal Apoptosis in ExperimentalStreptococcus pneumoniaeMeningitisThe Journal of Infectious Diseases, 2000